Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2880905 | 1.00 | HTR2C (0.54) | HTR2CKDM1ASLC18A3HTR2AHTR2B | |
| SCHEMBL2883946 | 1.00 | HTR2C (0.54) | HTR2CKDM1ASLC18A3HTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL2883295 | 0.98 | HTR2C (0.56) | HTR2CKDM1ASLC18A3HTR2AHTR2B | |
| SCHEMBL4472639 | 0.87 | HTR2C (0.57) | HTR2CKDM1AHTR2AHTR2BSLC6A2 | |
| SCHEMBL4481183 | 0.87 | HTR2C (0.57) | HTR2CKDM1AHTR2AHTR2BSLC6A2 | |
| SCHEMBL4472806 | 0.87 | HTR2C (0.57) | HTR2CKDM1AHTR2AHTR2BSLC6A2 | |
| SCHEMBL4462762 | 0.87 | HTR2C (0.57) | HTR2CKDM1AHTR2AHTR2BSLC6A2 | |
| SCHEMBL4474007 | 0.87 | HTR2C (0.57) | HTR2CKDM1AHTR2AHTR2BSLC6A2 | |
| SCHEMBL4477632 | 0.87 | HTR2C (0.57) | HTR2CKDM1AHTR2AHTR2BSLC6A2 | |
| SCHEMBL4473586 | 0.87 | HTR2C (0.57) | HTR2CKDM1AHTR2AHTR2BSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | HTR2C 699/4885KDM1A 3484/4885SLC18A3 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.